Last updated: 2026-09-28 13:00:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Lakewood-Amedex Biotherapeutics Inc. (LABT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.12, with a market capitalization of $3.96M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.62 to $98.20. This page covers its latest market performance, valuation, price trends and company information.
$3.96M | |
$1.65 | |
$98.20 | |
$1.62 | |
$1.67 | |
25.60M | |
1.85M | |
-- | |
$98.20 | |
$1.62 | |
-- | |
-- |
Lakewood-Amedex Biotherapeutics Inc. (LABT) is trading at $2.10 in pre-market trading as of 2026-09-28 12:44:36, up 25.87% ($0.43) from the previous close of $1.67
Pre-market trading shows how investors are pricing LABT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Lakewood-Amedex Biotherapeutics Inc. (LABT) moved from $1.86 to $2.12, representing a gain of 13.71% ($0.26).
The stock traded between $1.62 and $3.62 during the period. The latest price is near the lower end of the 7-day range, indicating strong upward.
The average daily volume was 185.54 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.5%
LABT is currently trading at $2.12, placing it 0.5% of the way from its 52-week low of $1.62 to its 52-week high of $98.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lakewood-Amedex Biotherapeutics Inc. (LABT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.